AzTrials
AzTrials

AnxietyPhase 2Endo-LoraNCT03180632

Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:

A Phase 2 study testing Lorazepam in people with Anxiety, run by St. Justine's Hospital at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the effect of a single dose of Lorazepam on salivary cortisol in children undergoing digestive endoscopy. To do so, the patients will be randomized in three groups. Read more about this study

Who is it for?
Ages 9 to 18 years
Conditions the study is for
Anxiety
What is being tested?
Lorazepam
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
98 participants
Where
1 siteCanada
Study dates
28 Jun 2017to 1 Jun 2018
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 9 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Children aged 9-18 seen in our endoscopic unit
  • Children undergoing upper, lower or combined digestive endoscopy
  • Procedure to be performed within 3 hours of inclusion in the study and drug administration

Who cannot join

  • Unable to read or speak English or French
  • Diagnosed with a psychiatric or neurological disorder
  • Myasthenia gravis
  • Acute narrow angle glaucoma
  • Known hypersensitivity to benzodiazepines
  • Already treated with an anxiolytic on a regular basis
Show all 10Show fewer
  • Receiving a drug contraindicated in association with benzodiazepines
  • Receiving oral, intravenous or inhaled corticosteroids in the last two days before randomization
  • Body weight less than 20 kg
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • CHU Sainte-Justine

    Montreal, Quebec, H3T 1C5

Other trials in Canada

About this study

Official title: Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: a Randomized Double Blinded Study

The purpose of this study is to determine the effect of a single dose of Lorazepam on salivary cortisol in children undergoing digestive endoscopy. To do so, the patients will be randomized in three groups. The first group receives the Lorazepam, the second group receives a placebo and the last group receives no intervention. Each patient will have three saliva samples taken at three different time point on the day of the endoscopy and will be asked to fill out questionnaires on anxiety and overall satisfaction of the procedure.

Read the detailed description

Background: Pediatric digestive endoscopies (gastroscopy and colonoscopy) are invasive procedures. All endoscopic procedure are conducted in the operating room either under intravenous (IV) sedation or general anesthesia. More than 50% of procedures are performed using IV sedation. The current sedation protocol in the endoscopy suite is a combination of Midazolam (0.1 mg/kg) and Fentanyl (1 microgram/kg) in all children. The children undergoing colonoscopies receive and additional administration of Ketamine (0.5 mg/kg).

In a previous study performed in children 10-18 years undergoing upper and lower endoscopy, the investigators found that despite this regimen, 25% of the children expressed a significantly high level of pain during endoscopy under IV sedation.

Because general anesthesia is not available for all children, it is important to investigate strategies that could help in minimizing the discomfort and pain during the procedure.

Salivary cortisol (sCortisol) has been used in several pediatric studies to determine the level of stress in children prior to various medical procedures. In another study done at our site, the investigators have found sCortisol to be a reliable biomarker of stress for children undergoing digestive endoscopies. Furthermore, the mean baseline sCortisol levels were higher in the group that experienced procedural pain.

Lorazepam is a a rapid onset benzodiazepine that has anxiolytic and sedative properties that has been approved by Health Canada as an adjunct therapy for the relief of excessive anxiety that might be present prior to surgical interventions.

Objective:

The primary objective is to investigate the effect of Lorazepam as compared to placebo on the change of the level of sCortisol between baseline (C1) and immediately before endoscopy (C2) in adolescents undergoing a gastroscopy or a colonoscopy. The investigators think that it might be possible to modulate the stress response with the administration of a benzodiazepine as soon as the children arrives at the hospital. Thus children could have a better experience of the digestive endoscopic procedure (less pain and more comfort).

The secondary outcome measure will be:

(1) the proportion of children experiencing procedural pain, (2) the duration of endoscopic procedures, (3) children satisfaction, (4) physician and nurse satisfaction (5) the total dose of Fentanyl and Ketamine per kilogram body weight delivered during the procedure and (6) the mean change between pre-op and postop cortisol levels between the two groups.

Safety outcomes measures: The following adverse events will be sought before and during the endoscopy: prolonged drowsiness, hypotension, hypertension, desaturation, bradycardia.

Exploratory outcomes: the mean change between pre-op and postop cortisol levels in the Group C (No intervention) compared to Group A and B.

Methods:

In this randomized controlled trial children will be assigned to one of the three following groups (no intervention, placebo and active drug). The investigators will collect salivary samples to measure the levels of sCortisol and investigate their variation between three timepoint ( at arrival at the hospital, right before the procedure and right after the procedure). sCortisol levels will be correlated to a questionnaire evaluating the anxiety level in the patient. The research team will also evaluate the pain experienced during the procedure using the Nurse-Assessed Patient Comfort Score (NAPCOMS): a validated tool for the evaluation of pain in subjects undergoing endoscopies).

Conditions
Anxiety
Being tested
Lorazepam, Placebo
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LorazepamDrug

    Also called Apo-Lorazepam

    Patient receives one or two tablet of 0,5mg Lorazepam according to body weight

  • PlaceboOther

    Patient receive one of two tablet of Placebo according to body weight

Study groups in NCT03180632
Study groupRoleWhat they receive
Group AActive comparatorPatient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
Receives: Drug: Lorazepam
Group BPlacebo comparatorPatient will receive a placebo similar in color, form and size.
Receives: Other: Placebo
Group 3No interventionPatient will receive no intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of sCortisol from baseline to one hour after drug administration

    Proportion of children with a decrease of sCortisol of at least 15 points between the group Placebo and the group Lorazepam

    Measured: One hour after drug administration

Secondary outcomes (7)
  1. Procedural pain

    Proportion of children experiencing procedural pain

    Measured: during endoscopic procedure

  2. Duration of endoscopic procedure

    Duration of endoscopic procedure. The time interval in minutes will be measured between the start and the end of each procedure.

    Measured: Through completion of endoscopy: an average of 2 hours after drug administration

  3. Children Satisfaction

    Children satisfaction will be evaluated with a validated Satisfaction questionnaire of children undergoing endoscopy

    Measured: Through study completion, an average of 3 hours

  4. Physician Satisfaction

    Physician satisfaction will be evaluated with a validated tool : CLINICIAN SATISFACTION WITH SEDATION INSTRUMENT (CSSI)

    Measured: during the endoscopic procedure

  5. Nurse Satisfaction

    Nurse satisfaction will be evaluated with a validated tool : NURSE ASSESSED PATIENT COMFORT SCORE (NAPCOMS)

    Measured: during the endoscopic procedure

  6. Medication needed For sedation

    Total dose of Fentanyl and Ketamine per kilogram body weight delivered

    Measured: during the procedure

  7. Change in sCortisol levels between pre-op and post-op

    Mean change between pre-op and post-op cortisol levels between the two groups (Lorazepam and Placebo)

    Measured: one hour after the endoscopic procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jun 2017
  2. Study start28 Jun 2017
  3. Primary completion1 Jun 2018
  4. Study completion1 Jun 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
98 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03180632
Sponsor's protocol ID
JP2017
Acronym
Endo-Lora
Status last verified
Sep 2018
First submitted
2 Jun 2017
Last updated
5 Sep 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Chennou F, Bonneau-Fortin A, Portolese O, Belmesk L, Jean-Pierre M, Cote G, Dirks MH, Jantchou P. Oral Lorazepam is not Superior to Placebo for Lowering Stress in Children Before Digestive Endoscopy: A Double-Blind, Randomized, Controlled Trial. Paediatr Drugs. 2019 Oct;21(5):379-387. doi: 10.1007/s40272-019-00351-9.

    PubMed 31418168

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Lorazepam in people with Anxiety, run by St. Justine's Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of sCortisol from baseline to one hour after drug administration (time frame: One hour after drug administration). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03180632, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in